WHO Sounds Alert Over Acute Shortage of Weight-Loss Jabs

Less than a tenth of individuals that would benefit from obesity jabs like Wegovy can access them, warns the WHO as it publishes its initial recommendations on the therapies.

With in excess of 1,000,000,000 people worldwide currently classified as obese, it is advocating for increased and just access to GLP-1 medication.

Per forecasts, more than two billion are projected to be living with obesity by 2030 if no action is taken.

"Our new guidelines recognises that obesity is a long-term condition that can be treated with comprehensive and continuous support," said its chief Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are significant obstacles to broad access to the jabs that can assist patients in reducing substantial weight, explains the agency.

Skinny Jab Shortage

Despite the current most favorable case, the production of these medications would only suffice for about 100 million people – fewer than 10% of eligible patients, as stated by the WHO.

The guideline calls on countries and companies to widen access, by approaches including licensing agreements.

A patent on a key compound – the primary ingredient of a leading brand – is scheduled to end in a number of nations in 2026.

How Obesity Injections Operate

These medications mimick a natural hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so users consume fewer calories.

People typically see weight reduction in the initial weeks of beginning the once-weekly jabs.

Research points to users may regain a significant portion a year later of discontinuing the medication, when their usual appetite resume.

To be carrying excess weight increases your chance for developing medical conditions, like type 2 diabetes, cardiovascular issues, brain attack, and specific malignancies.

Obesity impacts individuals in countries worldwide and was linked to 3.7 million deaths worldwide in 2024, as per the WHO.